Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)

September 28, 2021 by Novian Health

Groundbreaking laser therapy offers alternative to surgery for breast cancer

CHICAGO, Sept. 28, 2021 /PRNewswire/ — Novian Health Inc. has been granted Breakthrough Device designation from the U.S. Food and Drug Administration for its Novilase®Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women who seek a breast conserving procedure.

The FDA’s Breakthrough Device program supports the timely development of technologies that have the potential to provide more effective treatment of life-threatening diseases. By obtaining this status, Novian will benefit from an expedited regulatory review process, which may accelerate access to its interstitial laser therapy system in the United States.

“Laser therapy can help patients avoid the trauma and risks of breast cancer surgery,” said Henry Appelbaum, president and CEO of Novian Health. “Receiving this designation is a significant milestone that moves us one step closer to offering the benefits of this game-changing technology to breast cancer patients in the U.S.”

Novilase is a minimally invasive procedure that uses laser ablation to destroy tumors as an alternative to surgery. The intended use is for the focal destruction of malignant tumors of the breast up to 15 mm; for general surgery procedures including incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues.

Novilase has already been cleared in the U.S. for the treatment of benign breast tumors, or fibroadenomas. In addition, FDA granted an investigational device exemption for Novian Health’s pivotal study (BR-003), with enrollment anticipated to start in 2022 and study completion in 2023.

Novian received CE Mark approval to commercialize its technology in the European Union (EU) and Switzerland for the treatment of both malignant tumors and fibroadenomas, making it the first ablation device to have been cleared for malignant breast tumors.

More than 275,000 women in the U.S. and 2 million around the world are diagnosed with breast cancer every year. About two-thirds of early-stage breast cancer patients and their doctors will opt to remove the tumors surgically in a breast-conserving procedure called lumpectomy. This leaves a scar and can change the shape of a woman’s breast — and more than 25% of women will need additional surgery because their entire tumors were not removed during the initial surgical procedure.

During a Novilase procedure, doctors insert a laser probe directly into the tumor using ultrasound guidance in a manner similar to a breast biopsy. The tumor is then heated by the laser and destroyed. Intra-procedure confirmation of focal destruction is provided by a parallel temperature probe which records temperature at the periphery of the target ablation zone.

In contrast to a lumpectomy, which requires an operating room, general anesthesia, and several days of recovery, Novilase can be performed on an outpatient basis using local anesthesia, with minimal pain and a recovery time of hours instead of days. There is minimal scarring and no change in breast shape. Upon confirmation of focal destruction of the target tumor by MR imaging, patients will then proceed with recommended radiation and/or adjuvant therapies.

Multiple clinical trials have evaluated Novilase for the treatment of malignant breast tumors. A multi-center trial published in the Annals of Surgical Oncology in 2018 found that, for malignant breast tumors up to 15 mm, Novilase completely destroyed the tumor in 98% of patients. In addition, patients in the trial reported better health-related quality of life outcomes compared to lumpectomy surgery.

In 2020, Novian Health was recognized as one of MedTech Innovator’s Top 50 startups transforming the healthcare industry for its laser technology’s significant potential to transform the treatment of early-stage breast cancer. As the world’s largest medical device accelerator, MedTech assesses more than 1,000 startups each year to find the “most transformative device, diagnostic, and digital health technologies from around the globe.”

ABOUT NOVIAN HEALTH INC.

Based in Chicago, with a subsidiary in Evry, France, Novian Health Inc. is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy. For more information, call (312) 266-7200 or access www.novianhealth.com.

Contact: Liz Dowling, (415) 388-2794
Dowling & Dennis PR
Liz@dowlingdennis.net

Related Posts

  • Novian Health Obtains CE Mark for Novilase Breast Therapy (16 July 2019)
  • Novian Health Receives FDA Approval to Study Breast Cancer Therapy (14 July 2011)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)
  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)
  • Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors (2 Sept 2014)

Filed Under: Press Release 2021

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by